Hypo-fractionated regimen safe, feasible in elderly bladder cancer patients

In this interview with Robert A. Huddart, of the Institute of Cancer Research in the United Kingdom, we discuss results of the HYBRID trial, which tested a hypo-fractionated regimen of 36 Gy over six fractions in elderly muscle-invasive bladder cancer patients who were ineligible for standard treatment.
Cancer Network